BVS Earnings & Financial Statements
Bioventus Inc.
$13.88
+$0.38(+2.78%)
66
Overall
80
Value
70
Tech
50
Quality
Market Cap
$1.14B
Volume
56.30K
52W Range
$6.46 - $15.89
Target Price
$17.60
BVS earnings and financial statements: Bioventus Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
BVS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $568.09M | $573.28M | $512.35M | $512.12M | $430.90M |
| Cost of revenue | $179.93M | $185.05M | $184.15M | $181.04M | $128.19M |
| Operating income | $53.98M | -$15.20M | -$81.72M | -$167.23M | $12.06M |
| EBITDA | $99.21M | $36.01M | -$23.07M | -$121.61M | $42.49M |
| Net income | $22.73M | -$36.13M | -$156.23M | -$158.70M | $19.38M |
| EPS (diluted) | $0.33 | $-1.04 | $-2.49 | $-2.59 | $-0.15 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $683.56M | $727.96M | $810.91M | $1.37B | $1.23B |
| Total liabilities | $455.11M | $542.35M | $589.79M | $960.43M | $692.07M |
| Shareholders’ equity | $184.10M | $147.94M | $173.59M | $325.24M | $458.92M |
| Cash and equivalents | $51.24M | $41.58M | $36.96M | $30.19M | $43.93M |
| Long-term debt | $278.95M | $308.29M | $367.00M | $385.01M | $339.64M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $74.67M | $38.80M | $15.34M | -$13.54M | $22.99M |
| Capital expenditure | -$2.56M | -$1.01M | -$7.36M | -$1.48M | -$20.89M |
| Free cash flow | $72.11M | $37.79M | $7.98M | -$15.02M | $2.10M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BVS | $13.88 | +2.8% | 56.30K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |